News Archive

Chevy Chase venture fund New Enterprise Associates upped its bet on ThreatQuotient, a Reston-based cybersecurity analytics start-up, in a $12 million investment announced Tuesday.

ThreatQuotient operates a set of data analytics tools for corporate cybersecurity analysts, meant to help sort through the millions of data points that might predict the next hack. The company was founded in 2013 by two technologists working out of AOL’s Fishbowl Labs incubator in Sterling, Va., and chief executive John Czupak joined in late 2015.

The company, which employs more than 300 people at its plant in Ulverston, was praised for its work helping tackle diseases in both the western and developing world.

This list appeared in prestigious American publication Fortune, which has its headquarters in New York City.

The Institute of Human Virology (IHV) at the University of Maryland School of Medicine announced today a $14.4 million grant from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) to tackle a significant scientific global challenge in HIV vaccine research – the inability to produce long-lasting antibodies to protect against HIV infection. The announcement was made today by Robert C. Gallo, MD, The Homer & Martha Gudelsky Distinguished Professor of Medicine, Director, Institute of Human Virology, University of Maryland School of Medicine, and his colleagues George Lewis, PhD, Professor of Microbiology and Immunology, Director Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine and Anthony DeVico, PhD, Professor of Medicine, Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine. IHV’s grant collaborators include Guido Silvestri, MD at the Yerkes National Primate Research Center of Emory University and Warner Greene, MD, PhD, of the Gladstone Institute of Virology & Immunology at the University of California at San Francisco.

The Institute of Human Virology at the University of Maryland School of Medicine received a $14.4 million grant for HIV research.

The grant, awarded by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), will fund research aimed at tackling a significant scientific challenge in HIV vaccine research – the inability to produce long-lasting antibodies to protect against the infection.

New treatments are needed for severe asthmatics who do not respond to standard therapy with inhaled steroids, especially those with a “type 2 low” phenotype, such as individuals with neutrophil-predominant inflammation. This solicitation is for the development and early commercialization of an inhalational formulation of the 5A apolipoprotein A-I (apoA-I) mimetic peptide that can be administered to asthmatic subjects in Phase I clinical trials and subsequently developed into a new treatment for severe asthma.

Proposals will be due October 21, 5 pm and there will be a pre-proposal webinar on August 24, 2 pm (http://bit.ly/FY17ContractsWebinar) for companies who may be interested in applying.”

More and more people agree: cybersecurity is in our region’s DNA and can continue to be a boom for greater Washington.

But venture capital is pivotal in providing the accelerant for rapid growth of technology companies, and it I fear that the lack of sufficient risk capital is strangling some promising startups.

Venture capital (VC) financing fuels our future by investing in small, early-stage companies and projects that may be destined to become the next Apple or Google. A new report from Martin Prosperity Institute shows venture capital is highly concentrated by industry. The top five industries (in order) are as follows: software, biotechnology, media and entertainment, medical devices and equipment and information technology services.  According to the report, which uses detailed data from Thomson Reuters, these top five VC industries receive $25 billion in investment—more than three-quarters of the overall pie. If expanded to include the top 10 industries, we can account for more than 90 percent of all VC investment. The report focuses on the intersection of industry and geography for all VC investments.

You came to Hopkins in 2009 and now your contract has been extended through 2024. That’s a long time!

The board invited me to extend my term at Johns Hopkins, and I jumped at the opportunity. My wife and I love Hopkins and Baltimore, and couldn’t be happier knowing that we will be able to spend the next eight years being part of this amazing place, including, of course, strengthening Johns Hopkins’ relationship with Baltimore.

Joe Biden’s cancer moonshot might not be as far-fetched as you think.

Why? Because multiple U.S. agencies recently took steps to make the cancer moonshot a reality by further strengthening patent rights.